X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2346) 2346
Book Review (562) 562
Publication (219) 219
Book Chapter (16) 16
Conference Proceeding (8) 8
Dissertation (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2031) 2031
humans (1435) 1435
animals (1131) 1131
glucose (913) 913
male (836) 836
diabetes mellitus, type 2 - drug therapy (825) 825
sodium-glucose transporter 2 - antagonists & inhibitors (769) 769
diabetes (637) 637
hypoglycemic agents - therapeutic use (608) 608
endocrinology & metabolism (604) 604
type 2 diabetes (577) 577
glucose - metabolism (553) 553
female (539) 539
dextrose (513) 513
dapagliflozin (419) 419
sodium-glucose transporter 2 - metabolism (418) 418
rats (411) 411
sodium-glucose transporter 1 - metabolism (396) 396
glucosides - therapeutic use (389) 389
pharmacology & pharmacy (372) 372
sodium (369) 369
double-blind (358) 358
middle aged (351) 351
diabetes mellitus (335) 335
insulin (324) 324
hypoglycemic agents - adverse effects (315) 315
hypoglycemic agents - pharmacology (311) 311
blood glucose - metabolism (309) 309
sodium-glucose transporter 1 (308) 308
mice (301) 301
physiology (299) 299
canagliflozin (282) 282
hyperglycemia (279) 279
diabetes mellitus, type 2 - blood (262) 262
benzhydryl compounds - therapeutic use (260) 260
treatment outcome (255) 255
diabetes mellitus, type 2 - metabolism (252) 252
sglt2 inhibitor (250) 250
glucose metabolism (247) 247
glycemic control (242) 242
analysis (240) 240
empagliflozin (240) 240
glucosides - pharmacology (232) 232
expression (226) 226
adult (224) 224
aged (224) 224
blood glucose - drug effects (219) 219
type 2 diabetes mellitus (219) 219
monosaccharide transport proteins - metabolism (218) 218
biochemistry & molecular biology (215) 215
metformin (215) 215
type-2 diabetes-mellitus (206) 206
kidney - metabolism (204) 204
sodium-glucose transporter 1 - genetics (204) 204
rodents (201) 201
safety (197) 197
mellitus (196) 196
hypoglycemic agents - administration & dosage (195) 195
hypoglycemic agents (193) 193
glucosides - adverse effects (186) 186
diabetes mellitus, type 2 - complications (185) 185
sglt2 (185) 185
risk factors (184) 184
sglt1 (183) 183
membrane glycoproteins - metabolism (182) 182
care and treatment (180) 180
inadequate glycemic control (178) 178
metabolism (172) 172
research (172) 172
internal medicine (169) 169
sglt2 inhibitors (169) 169
blood pressure (161) 161
sodium - metabolism (160) 160
kidney (159) 159
efficacy (153) 153
medicine & public health (151) 151
drug therapy (147) 147
cell biology (146) 146
glucose transporter (146) 146
glycated hemoglobin a - metabolism (146) 146
clinical trials (145) 145
benzhydryl compounds - pharmacology (143) 143
dose-response relationship, drug (141) 141
abridged index medicus (140) 140
absorption (140) 140
rats, sprague-dawley (139) 139
na+/glucose cotransporter (138) 138
physiological aspects (137) 137
proteins (136) 136
body weight (135) 135
drug therapy, combination (134) 134
diabetes therapy (132) 132
transport (131) 131
gene expression (129) 129
kidney - drug effects (127) 127
monosaccharide transport proteins - genetics (127) 127
benzhydryl compounds - adverse effects (126) 126
health aspects (126) 126
insulin resistance (125) 125
blood-pressure (124) 124
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2269) 2269
German (23) 23
Japanese (15) 15
Spanish (11) 11
Chinese (7) 7
French (6) 6
Russian (6) 6
Korean (5) 5
Czech (3) 3
Dutch (2) 2
Swedish (2) 2
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1322 - 1326
Journal Article
Nature Medicine, ISSN 1078-8956, 05/2015, Volume 21, Issue 5, pp. 512 - 517
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2017, Volume 19, Issue 9, pp. 1289 - 1294
AimTo quantify the expression of sodium-glucose co-transporter (SGLT)2 and SGLT1, their cognate basolateral transporters, GLUT2 and GLUT1, and the... 
type 2 diabetes | clinical physiology | inhibitor | SGLT2 | SGLT2 inhibitor | RAT | TRANSPORTERS | ALBUMINURIA | PROXIMAL TUBULAR CELLS | GLOMERULAR HYPERFILTRATION | NEPHROPATHY | HYPERGLYCEMIA | PROTEIN EXPRESSION | ENDOCRINOLOGY & METABOLISM | BRUSH-BORDER MEMBRANE | KIDNEY | Kidney Tubules - physiopathology | Kidney - pathology | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 1 - genetics | Kidney Neoplasms - surgery | Kidney - metabolism | Carcinoma - complications | Kidney Neoplasms - physiopathology | Nephrectomy | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Female | Retrospective Studies | Sodium-Glucose Transporter 1 - metabolism | Kidney Tubules - pathology | Carcinoma - pathology | Kidney Neoplasms - complications | Kidney Tubules - metabolism | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Sodium-Glucose Transporter 2 - genetics | Hypoglycemic Agents - therapeutic use | Reproducibility of Results | Glomerular Filtration Rate | Kidney - drug effects | Kidney Tubules - drug effects | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Sodium-Glucose Transporter 2 - metabolism | Carcinoma - surgery | Carcinoma - physiopathology | Gene Expression Regulation - drug effects | Kidney Neoplasms - pathology | Aged | Diabetes Mellitus, Type 2 - pathology | Diabetes Mellitus, Type 2 - drug therapy | Neoplasm Staging | Type 2 diabetes | Immunohistochemistry | Viral antibodies | Care and treatment | Antibodies | Glucose | Muscle proteins | Dextrose | Diabetes | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, pp. e54442 - e54442
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patients with diabetes mellitus. SGLT2 inhibitors block... 
MATRIX | STIMULATION | MULTIDISCIPLINARY SCIENCES | DISEASE | HIGH GLUCOSE | GENE-EXPRESSION | MESANGIAL CELLS | PPAR-GAMMA AGONISTS | MELLITUS | TRANSFORMING GROWTH FACTOR-BETA | Diabetes Mellitus - pathology | Epithelial Cells - metabolism | Gene Expression - drug effects | Diabetes Mellitus - genetics | Transcription Factor AP-1 - genetics | Epithelial Cells - drug effects | Humans | Diabetic Nephropathies - drug therapy | NF-kappa B - metabolism | Smad3 Protein - metabolism | Transcription Factor AP-1 - metabolism | Sodium-Glucose Transporter 1 - genetics | Smad3 Protein - genetics | Sodium-Glucose Transporter 1 - metabolism | Phosphorylation - drug effects | Interleukin-6 - metabolism | Transforming Growth Factor beta1 - pharmacology | Sodium-Glucose Transporter 2 - genetics | Collagen Type IV - metabolism | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Promoter Regions, Genetic | Diabetic Nephropathies - pathology | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Interleukin-6 - genetics | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Diabetes Mellitus - drug therapy | Diabetes Mellitus - metabolism | Toll-Like Receptor 4 - genetics | Diabetic Nephropathies - genetics | Epithelial Cells - pathology | Glucose - pharmacology | Toll-Like Receptor 4 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | NF-kappa B - genetics | Kidney Tubules, Proximal - metabolism | Collagen Type IV - genetics | Protein Binding | Benzhydryl Compounds - pharmacology | Kidney Tubules, Proximal - drug effects | Physiological aspects | Care and treatment | Genetic aspects | Research | Transforming growth factors | Diabetic nephropathies | Chromatin | Immunoprecipitation | Transforming growth factor-b | Interleukin | Clinical trials | Systematic review | Smad3 protein | Glucose | Kinases | Interleukin 6 | Proteins | Hyperglycemia | Rodents | Toll-like receptors | Collagen (type IV) | Hypoglycemic agents | Inhibition | Growth factors | Deoxyribonucleic acid--DNA | Binding | Glucose transporter | Medical research | NF-κB protein | Secretion | Diabetes mellitus | Markers | Activator protein 1 | Blocking | Reabsorption | Inflammation | Gene expression | Glucose transport | Immune systems | Medicine | High mobility group proteins | Hospitals | Inhibitors | Nephropathy | Sodium | Fibrosis | Kidney diseases | Diabetes | Transporter | Adenosine triphosphatase | Kidney transplantation | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 10/2013, Volume 170, Issue 3, pp. 519 - 531
Background and PurposeAlthough inhibition of renal sodium-glucose co-transporter 2 (SGLT2) has a stable glucose-lowering effect in patients with type 2... 
tofogliflozin | nephropathy | beta‐cell loss | sodium–glucose co‐transporter inhibitor | sodium-glucose co-transporter inhibitor | beta-cell loss | SYSTEM | METFORMIN | SELECTIVE SGLT2 INHIBITOR | GLYCEMIC CONTROL | EFFICACY | DAPAGLIFLOZIN TREATMENT | GLOMERULAR HYPERFILTRATION | DIABETES-MELLITUS | INSULIN | PHARMACOLOGY & PHARMACY | KIDNEY | Kidney - pathology | Diabetic Nephropathies - etiology | Glycated Hemoglobin A - metabolism | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Angiotensin II Type 1 Receptor Blockers - pharmacology | Insulin-Secreting Cells - metabolism | Kidney - metabolism | Diabetic Nephropathies - physiopathology | Time Factors | Female | Albuminuria - metabolism | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Disease Models, Animal | Glucosides - pharmacology | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Losartan - pharmacology | Biomarkers - blood | Albuminuria - prevention & control | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Animals | Diabetes Mellitus, Type 2 - physiopathology | Insulin-Secreting Cells - drug effects | Benzhydryl Compounds - pharmacology | Mice | Insulin-Secreting Cells - pathology | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Glucose metabolism | Pancreatic beta cells | Image processing | Blood sugar | Analysis | Angiotensin | Equipment and supplies | Glucose | Diabetes | Sodium | Pancreas | Insulin | Rodents | Index Medicus | Research Papers | sodium–glucose co-transporter inhibitor
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, pp. e30555 - e30555
Background: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM).... 
SELECTIVE SGLT2 INHIBITOR | SODIUM | HYPERGLYCEMIA | DAPAGLIFLOZIN | TRANSPORTERS | MULTIDISCIPLINARY SCIENCES | INSULIN-SECRETION | COTRANSPORTER INHIBITOR T-1095 | RATS | PROXIMAL TUBULAR CELLS | MELLITUS | Thiophenes - therapeutic use | Diabetes Mellitus, Experimental - drug therapy | Humans | Body Weight - drug effects | Male | Muscle, Skeletal - metabolism | Muscle, Skeletal - cytology | Hyperglycemia - drug therapy | Sodium-Glucose Transporter 1 - genetics | Muscle, Skeletal - drug effects | Hyperglycemia - pathology | Sodium-Glucose Transport Proteins - metabolism | Glucosides - therapeutic use | Weight Gain - drug effects | Sodium-Glucose Transporter 1 - metabolism | Diabetes Mellitus, Experimental - metabolism | Kidney - physiopathology | Sodium-Glucose Transport Proteins - genetics | CHO Cells | Sodium-Glucose Transporter 2 - genetics | Cricetinae | Glucose Tolerance Test | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Mice, Inbred C57BL | Cells, Cultured | Rats | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hyperglycemia - metabolism | Rats, Zucker | Animals | Canagliflozin | Diabetes Mellitus, Experimental - pathology | Mice, Obese | Mice | Blood Glucose - metabolism | Type 2 diabetes | Glucose metabolism | Obesity | Blood sugar | Analysis | Body weight | Glycosylated hemoglobin | Diabetes therapy | Cell culture | Animal models | Renal function | Laboratories | Liver | Homeostasis | Fuel consumption | Diabetic neuropathy | Glucose | Oocytes | Hyperglycemia | Rodents | Hemoglobin | Glucose transporter | Excretion | Kidneys | Secretion | Research & development--R&D | Diabetes mellitus | Pharmacology | Insulin | Body weight gain | Myoblasts | Beta cells | Sodium | Weight reduction | Insulin resistance | Diabetes | Mutation | Transporter | Kidney transplantation | Pharmaceuticals | Index Medicus | Research & development | R&D
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 458 - 462
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2015, Volume 112, Issue 30, pp. E4111 - E4119
Journal Article
American Journal of Physiology - Renal Physiology, ISSN 0363-6127, 01/2013, Volume 304, Issue 2, pp. F156 - F157
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 02/2014, Volume 124, Issue 2, pp. 499 - 508
Journal Article
Circulation, ISSN 0009-7322, 07/2017, Volume 136, Issue 3, pp. 249 - 259
Journal Article